Key Figures in millions of CHF

	2007	2006	%change	%change	2007	2006
			CHF	LC	% of sales	% of sales
Sales	22,827	19,849	+15%	+15%
Research and development	3,635	3,063	+19%	+21	15.9	15.4
EBITDA 1)	8,703	7,061	+23%	+22%	38.1	35.6
Operating profit	7,477	5,805	+29%	+27%	32.8	29.2
Net income	5,862	4,543	+29%		25.7	22.9
Core EPS 2)	5.95	4.90	+21%

	30 June 2007	31 December 2006	30 June 2006
Net cash	15,626	16,088	11,965
Equity	50,465	46,814	41,520
Equity ratio	65.9%	62.9%	61.0%

1) EBITDA: Earnings before financial income, financing costs, tax, depreciation and amortisation, including impairment. This corresponds to operating profit before depreciation and amortisation, including impairment.
2) See page 48 of the Half-Year Report for definition of Core EPS.
LC = local currencies.



Sales by Division in millions of CHF

		% change in CHF	% change in LC	as % of sales
Pharmaceuticals Division
Sales	18,268	+17%	+18%	100
- Roche Pharmaceuticals	11,367	+18%	+16%	62
- Genentech	5,227	+24%	+28%	29
- Chugai	1,674	-1%	+7%	9
EBITDA	7,424	+27%	+26%	40.6
Operating profit	6,640	+32%	+31%	36.3
Diagnostics Division
Sales	4,559	+7%	+5%	100
- Professional Diagnostics	2,110	+8%	+6%	46
- Diabetes Care	1,544	+8%	+6%	34
- Molecular Diagnostics	574	-3%	-2%	13
- Applied Science	331	+9%	+9%	7
EBITDA	1,389	+4%	+3%	30.5
Operating profit	949	+4%	+3%	20.8

LC = local currencies.



Sales by Region in millions of CHF

	% of sales	% change in LC
Pharmaceuticals Division
North America	42	+24%
Europe	34	+16%
Latin America	6	+15%
Japan	9	+7%
Other regions	9	+15%
Diagnostics Division
North America	26	+5%
Europe / Middle East / Africa	56	+5%
Latin America	5	+15%
Asia-Pacific	8	+18%
Japan	4	-1%
Other regions	1	-61%

LC = local currencies.